Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CEL | P19835 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503386 | 0.72 | CEL (0.34) | NR1I2HSD11B1CEL | |
| SCHEMBL7594171 | 0.72 | — | — | |
| SCHEMBL6040440 | 0.68 | — | — | |
| SCHEMBL18167344 | 0.68 | TDO2 (0.40) | TDO2 | |
| SCHEMBL25257005 | 0.66 | PDE10A (0.31) | — | |
| SCHEMBL2647857 | 0.65 | TDP1 (0.40) | CEL | |
| SCHEMBL31524176 | 0.65 | TDP1 (0.40) | CEL | |
| SCHEMBL30833923 | 0.65 | TDP1 (0.40) | CEL | |
| SCHEMBL31255118 | 0.64 | KMT2A (0.37) | TDO2CEL | |
| SCHEMBL384814 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142178-A1 | Method of treating cancer | BARNETT STANLEY F | 2006-06-29 | — | — | US | disclosed |
| US-20040106540-A1 | Method of treating cancer | BARNETT STANLEY F (US) | 2004-06-03 | — | — | US | disclosed |
| US-20040102360-A1 | Combination therapy | BARNETT STANLEY F (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1379250-A2 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002083064-A2 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102360-A1 | Combination therapy | MTOR, AKT2, PLK1 | TDO2 4643/4885NR1I2 3869/4885HSD11B1 4008/4885 |
| US-20060142178-A1 | Method of treating cancer | PACSIN2, CTTN, TNK2 | TDO2 4718/4885NR1I2 4331/4885HSD11B1 2319/4885 |
| US-20040106540-A1 | Method of treating cancer | PACSIN2, CTTN, PLK1 | TDO2 4762/4885NR1I2 4361/4885HSD11B1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.